One dose of experimental therapy reduced lipoprotein(a) more than 94% for nearly a year
November 14, 2023
November 14, 2023
DALLAS, Texas, Nov. 14 [Category: Health Care] -- The American Heart Association issued the following news release:
Research Highlights:
In this first trial in people, a single dose of a new therapeutic called lepodisiran reduced the harmful risk factor lipoprotein(a), or Lp(a), by up to 94%, with reductions lasting nearly a year.
Lepodisiran is a small interfering RNA that lowers Lp(a) by blocking the production in the liver of a key protein component of t . . .
Research Highlights:
In this first trial in people, a single dose of a new therapeutic called lepodisiran reduced the harmful risk factor lipoprotein(a), or Lp(a), by up to 94%, with reductions lasting nearly a year.
Lepodisiran is a small interfering RNA that lowers Lp(a) by blocking the production in the liver of a key protein component of t . . .